{"id":"depigoid-parietaria-judaica-1000dpp-ml","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (itching, swelling, erythema)"},{"rate":null,"effect":"Oral allergy syndrome or local oral symptoms"},{"rate":null,"effect":"Systemic allergic reactions"},{"rate":null,"effect":"Rhinitis or asthma exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Depigoid contains standardized allergen extracts from Parietaria judaica (wall pellitory) pollen and works through allergen immunotherapy (AIT) principles. By administering increasing doses of the allergen, it promotes immune tolerance through shift toward regulatory T cells and IgG-blocking antibodies, thereby reducing IgE-mediated allergic reactions. This approach is designed to provide long-term clinical benefit and reduce symptoms in allergic rhinitis and potentially allergic asthma.","oneSentence":"Depigoid is an allergen extract-based immunotherapeutic that desensitizes the immune system to Parietaria judaica pollen through gradual exposure, reducing allergic responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:02.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis caused by Parietaria judaica pollen sensitization"},{"name":"Allergic asthma associated with Parietaria judaica pollen allergy"}]},"trialDetails":[{"nctId":"NCT00916760","phase":"PHASE3","title":"Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica","status":"COMPLETED","sponsor":"Laboratorios Leti, S.L.","startDate":"2008-02","conditions":"Allergic Rhinoconjunctivitis","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["A suspension of depigmented and glutaraldehyde-polymerised allergen extract of Parietaria judaica adsorbed onto aluminium hydroxide."],"phase":"phase_3","status":"active","brandName":"Depigoid Parietaria judaica 1000DPP/ml","genericName":"Depigoid Parietaria judaica 1000DPP/ml","companyName":"Laboratorios Leti, S.L.","companyId":"laboratorios-leti-s-l","modality":"Biologic","firstApprovalDate":"","aiSummary":"Depigoid is an allergen extract-based immunotherapeutic that desensitizes the immune system to Parietaria judaica pollen through gradual exposure, reducing allergic responses. Used for Allergic rhinitis caused by Parietaria judaica pollen sensitization, Allergic asthma associated with Parietaria judaica pollen allergy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}